Evaluation of the effects of AZD3480 on cardiac repolarization: A thorough QT/QTc study using moxifloxacin as a positive control

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 4, 2010, Pages 532-539

  Dalen P ^a   Vik, T ^b   Alverlind, S ^a   Jostell, K G ^a   Hrdemark, H G ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ISPRONICLINE; MOXIFLOXACIN; PLACEBO; ANTIINFECTIVE AGENT; CYTOCHROME P450 2D6; HETEROCYCLIC COMPOUND; NICOTINIC AGENT; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; DRUG EFFECTS; ELECTROCARDIOGRAPHY; GENETICS; GENOTYPE; HEART; HEART RATE; PHYSIOLOGY;

ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FLUOROQUINOLONES; GENOTYPE; HEART; HEART RATE; HUMANS; MALE; NICOTINIC AGONISTS; PYRIDINES; QUINOLINES;

EID: 77957018431     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.131     Document Type: Article

References (15)

1. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Accessed 15 May 2009.
2. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13 (2005).
3. Ingelman-Sundberg, M., Sim, S.C., Gomez, A. & Rodriguez-Antona, C . Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526 (2007).
4. Roden, D.M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350, 1013-1022 (2004).
5. Fenichel, R.R. et al.; Independent Academic Task Force. Drug-induced torsades de pointes and implications for drug development. J. Cardiovasc. Electrophysiol. 15, 475-495 (2004).
6. Morganroth, J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin. Pharmacol. Ther. 81, 108-113 (2007).
7. Davies, A.J., Harindra, V., McEwan, A. & Ghose, R.R. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 298, 325 (1989).
8. Wysowski, D.K., Corken, A., Gallo-Torres, H., Talarico, L. & Rodriguez, E.M. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am. J. Gastroenterol. 96, 1698-1703 (2001).
9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non- Antiarrhythmic Drugs: E14 Geneva, Switzerland, 2005.
10. Démolis, J.L., Kubitza, D., Tennezé, L. & Funck-Brentano, C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin. Pharmacol. Ther. 68, 658-666 (2000).
11. Bloomfield, D.M. et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin. Pharmacol. Ther. 84, 475-480 (2008).
12. Fattinger, K., Verotta, D. & Benowitz, N.L. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J. Pharmacol. Exp. Ther. 281, 1238-1246 (1997).
13. Quick, M.W. & Lester, R.A.J. Desensitization of neuronal nicotinic receptors. J. Neurobiol. 53, 457-478 (2002).
14. Brown, C.D. et al. Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol. Appl. Pharmacol. 233, 428-438 (2008).
15. Andreev, E., Koopman, M. & Arisz, L. Rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J. Intern. Med. 246, 247-252 (1999).